Introduction

The increasing prevalence of resistant bacteria such as fluoroquinolone-resistant or extended-spectrum b-lactamase-producing strains in pathogens causing acute uncomplicated cystitis has been of concern. Faropenem sodium is a penem antimicrobial that demonstrates a wide antimicrobial spectrum against both aerobic and anaerobic bacteria. It is stable against several b-lactamases.

Aim

To evaluate the efficacy of faropenem against cystitis and to determine the optimal faropenem treatment duration.

Patient Profile

• Women aged ≥20 years, with any cystitis symptoms, such as micturition pain, urinary frequency, urge to urinate, or lower abdominal pain with pyuria and bacteriuria
• Target bacteria: Staphylococcus spp., Enterococcus faecalis, Streptococcus agalactiae and Enterobacteriaceae

Methods

• Multicentre, randomized, open-label, controlled study comparing 3- and 7-day administration regimens of faropenem
• Treatment: 200 mg faropenem sodium tablet administered three times daily (600 mg/day) for 3 or 7 days

Study endpoints

• Primary: Microbiological outcome 5–9 days after treatment completion
• Second endpoint: Clinical outcome 5–9 days or 4–6 weeks after treatment

Results

• E. coli accounted for 73.9% of the isolated bacterial strains. Highest faropenem MIC was 2 mg/L and this strain was eradicated after 7 days of treatment
• Clinical efficacies 5-9 days after treatment in 3-days and 7-days groups: 76.7% vs. 80.2% (P=0.695)
• Clinical efficacies 4-6 weeks after treatment completion in 3-days and 7-days groups: 46.2% vs. 50.0% (P=0.717)

Table 1: Comparison of Study Endpoints

Safety: Adverse events due to faropenem were reported in 9.5% of participants and most common adverse event was diarrhoea.

Conclusion

• Optimal regimen of faropenem for cystitis was determined to be 200 mg three times daily for 7 days
• E. coli strains resistant to fluoroquinolones or cephalosporins showed high susceptibility to faropenem

Reference

J Antimicrob Chemother 2014; 69: 1675–1680

Introduction

The increasing prevalence of resistant bacteria such as fluoroquinolone-resistant or extended-spectrum b-lactamase-producing strains in pathogens causing acute uncomplicated cystitis has been of concern. Faropenem sodium is a penem antimicrobial that demonstrates a wide antimicrobial spectrum against both aerobic and anaerobic bacteria. It is stable against several b-lactamases.

Aim

To evaluate the efficacy of faropenem against cystitis and to determine the optimal faropenem treatment duration.

Patient Profile

Methods

Study endpoints

Results

Table 1: Comparison of Study Endpoints

Safety: Adverse events due to faropenem were reported in 9.5% of participants and most common adverse event was diarrhoea.

Conclusion

Reference

J Antimicrob Chemother 2014; 69: 1675–1680